公开(公告)号：US09925157B2

公开(公告)日：2018-03-27

申请号：US15656884

申请日：2017-07-21

Applicant: The Regents of the University of California

Inventor： Ranjan Dohil ,  Jerry Schneider

IPC: A01N33/08 ,  A61K31/194 ,  A61K9/28 ,  A61K9/50 ,  A61K9/48 ,  A61K9/00 ,  A61K31/145 ,  A61K31/13 ,  A61K9/16

CPC classification number: A61K31/194 ,  A61K9/0053 ,  A61K9/1605 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2873 ,  A61K9/288 ,  A61K9/4808 ,  A61K9/5005 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5057 ,  A61K9/5063 ,  A61K31/13 ,  A61K31/145

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

公开(公告)号：US09511039B2

公开(公告)日：2016-12-06

申请号：US14950234

申请日：2015-11-24

Applicant: The Regents of the University of California

Inventor： Ranjan Dohil ,  Jerry Schneider

IPC: A01N33/08 ,  A61K31/145 ,  A61K31/13 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K9/28

CPC classification number: A61K31/194 ,  A61K9/0053 ,  A61K9/1605 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2873 ,  A61K9/288 ,  A61K9/4808 ,  A61K9/5005 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5057 ,  A61K9/5063 ,  A61K31/13 ,  A61K31/145

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

公开(公告)号：US20150283100A1

公开(公告)日：2015-10-08

申请号：US14555993

申请日：2014-11-28

Applicant: The Regents of the University of California

Inventor： Ranjan Dohil ,  Jerry Schneider

IPC: A61K31/145

CPC classification number: A61K31/194 ,  A61K9/0053 ,  A61K9/1605 ,  A61K9/1635 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2873 ,  A61K9/288 ,  A61K9/4808 ,  A61K9/5005 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5057 ,  A61K9/5063 ,  A61K31/13 ,  A61K31/145

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Abstract translation: 本公开提供了可用于治疗胱氨酸沉积和神经变性疾病和病症的口服半胱胺和胱胺胺制剂。 该制剂提供控制释放组合物，其改善生活质量并减少副作用。

公开(公告)号：US20170319523A1

公开(公告)日：2017-11-09

申请号：US15656884

申请日：2017-07-21

Applicant: The Regents of the University of California

Inventor： Ranjan Dohil ,  Jerry Schneider

IPC: A61K31/194 ,  A61K9/00 ,  A61K9/50 ,  A61K9/48 ,  A61K9/28 ,  A61K9/16 ,  A61K31/13 ,  A61K31/145

CPC classification number: A61K31/194 ,  A61K9/0053 ,  A61K9/1605 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2873 ,  A61K9/288 ,  A61K9/4808 ,  A61K9/5005 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5057 ,  A61K9/5063 ,  A61K31/13 ,  A61K31/145

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

公开(公告)号：US20170319522A1

公开(公告)日：2017-11-09

申请号：US15656863

申请日：2017-07-21

Applicant: The Regents of the University of California

Inventor： Ranjan Dohil ,  Jerry Schneider

IPC: A61K31/194 ,  A61K9/00 ,  A61K9/50 ,  A61K9/48 ,  A61K9/28 ,  A61K9/16 ,  A61K31/13 ,  A61K31/145

CPC classification number: A61K31/194 ,  A61K9/0053 ,  A61K9/1605 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2873 ,  A61K9/288 ,  A61K9/4808 ,  A61K9/5005 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5057 ,  A61K9/5063 ,  A61K31/13 ,  A61K31/145

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

公开(公告)号：US20170304233A1

公开(公告)日：2017-10-26

申请号：US15362782

申请日：2016-11-28

Applicant: The Regents of the University of California

Inventor： Ranjan Dohil ,  Jerry Schneider

IPC: A61K31/145 ,  A61K45/06 ,  A61K9/48

CPC classification number: A61K31/145 ,  A61K9/4891 ,  A61K45/06 ,  A61K2300/00

Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US09198882B2

公开(公告)日：2015-12-01

申请号：US14752383

申请日：2015-06-26

Applicant: The Regents of the University of California

Inventor： Ranjan Dohil ,  Jerry Schneider

IPC: A01N33/08 ,  A61K31/145 ,  A61K9/00

CPC classification number: A61K31/194 ,  A61K9/0053 ,  A61K9/1605 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2873 ,  A61K9/288 ,  A61K9/4808 ,  A61K9/5005 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5057 ,  A61K9/5063 ,  A61K31/13 ,  A61K31/145

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

公开(公告)号：US20150290149A1

公开(公告)日：2015-10-15

申请号：US14752383

申请日：2015-06-26

Applicant: The Regents of the University of California

Inventor： Ranjan Dohil ,  Jerry Schneider

IPC: A61K31/145 ,  A61K9/00

CPC classification number: A61K31/194 ,  A61K9/0053 ,  A61K9/1605 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2873 ,  A61K9/288 ,  A61K9/4808 ,  A61K9/5005 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5057 ,  A61K9/5063 ,  A61K31/13 ,  A61K31/145

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

公开(公告)号：US11311507B2

公开(公告)日：2022-04-26

申请号：US16684000

申请日：2019-11-14

Applicant: The Regents of the University of California

Inventor： Ranjan Dohil ,  Jerry Schneider

IPC: A01N33/08 ,  A61K31/194 ,  A61K9/28 ,  A61K31/13 ,  A61K9/16 ,  A61K31/145 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

公开(公告)号：US09795578B2

公开(公告)日：2017-10-24

申请号：US15224414

申请日：2016-07-29

Applicant: The Regents of the University of California

Inventor： Ranjan Dohil ,  Jerry Schneider

IPC: A01N33/08 ,  A61K31/194 ,  A61K9/28 ,  A61K31/13 ,  A61K31/145 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K9/16

CPC classification number: A61K31/194 ,  A61K9/0053 ,  A61K9/1605 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2873 ,  A61K9/288 ,  A61K9/4808 ,  A61K9/5005 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5057 ,  A61K9/5063 ,  A61K31/13 ,  A61K31/145

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.